Health-related quality of life in patients with melanoma expressed as utilities and disability weights

British Journal of Dermatology

Volumn 171, Issue 6, 2014, Pages 1443-1450

  Tromme, I ^a   Devleesschauwer, B ^a   Beutels, P ^b   Richez, P ^a   Leroy, A ^a   Baurain, J F ^a   Cornelis, F ^a   Bertrand, C ^a   Legrand, N ^a   Degueldre, J ^c   Thomas, L ^d   Legrand, C ^a   Lambert, J ^e   Haagsma, J ^f   Speybroeck, N ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^d UNIVERSITÉ LYON 1   (France)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER REGRESSION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CUTANEOUS MELANOMA; DISABILITY; DISABILITY WEIGHT; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; TREATMENT DURATION; VISUAL ANALOG SCALE; ADOLESCENT; COST OF ILLNESS; DISABLED PERSON; HEALTH STATUS; MELANOMA; MIDDLE AGED; PSYCHOLOGY; QUALITY OF LIFE; SKIN NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COST OF ILLNESS; DISABLED PERSONS; FEMALE; HEALTH STATUS; HUMANS; MALE; MELANOMA; MIDDLE AGED; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84919460286     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13262     Document Type: Article

References (43)

1. Cornish D, Holterhues C, van de Poll-Franse LV, et al,. A systematic review of health-related quality of life in cutaneous melanoma. Ann Oncol 2009; 20 (Suppl. 6): vi51-8.
2. Kasparian NA, McLoone JK, Butow PN,. Psychological responses and coping strategies among patients with malignant melanoma: a systematic review of the literature. Arch Dermatol 2009; 145: 1415-27.
3. Gibbons E, Casañas i Comabella C, Fitzpatrick R,. A structured review of patient-reported outcome measures for patients with skin cancer, 2013. Br J Dermatol 2013; 168: 1176-86.
4. Cormier JN, Ross MI, Gershenwald JE, et al,. Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. Cancer 2008; 112: 2249-57.
5. Bendeck SE, Hadley JC, Bonaccorsi P, et al,. Can melanoma patients predict the quality of life impact of an alternate melanoma stage? Presented at the 26th Annual Meeting of the Society for Medical Decision Making, Atlanta, GA, U.S.A., 17-20 October 2004; P1530.
6. Bendeck SE, Hadley JC, Bonaccorsi P, et al,. Quality of life impact by melanoma as measured by utilities. Presented at the 26th Annual Meeting of the Society for Medical Decision Making, Atlanta, GA, U.S.A., 17-20 October 2004; P1524.
7. Hirst NG, Gordon LG, Scuffham PA, Green AC,. Lifetime cost-effectiveness of skin cancer prevention through promotion of daily sunscreen use. Value Health 2012; 15: 261-8.
8. Losina E, Walensky RP, Geller A, et al,. Visual screening for malignant melanoma: a cost-effectiveness analysis. Arch Dermatol 2007; 143: 21-8.
9. Morton RL, Howard K, Thompson JF,. The cost-effectiveness of sentinel node biopsy in patients with intermediate thickness primary cutaneous melanoma. Ann Surg Oncol 2009; 16: 929-40.
10. Wilson EC, Emery JD, Kinmonth AL, et al,. The cost-effectiveness of a novel SIAscopic diagnostic aid for the management of pigmented skin lesions in primary care: a decision-analytic model. Value Health 2013; 16: 356-66.
11. King SM, Bonaccorsi P, Bendeck S, et al,. Melanoma quality of life: pilot study using utility measurements. Arch Dermatol 2011; 147: 353-4.
12. Brennan DS, Spencer AJ,. Disability weights for the burden of oral disease in South Australia. Popul Health Metr 2004; 2: 7.
13. Essink-Bot ML, Pereira J, Packer C, et al,. Cross-national comparability of burden of disease estimates: the European Disability Weights Project. Bull World Health Organ 2002; 80: 644-52.
14. Haagsma JA, Polinder S, van Beeck EF, et al,. Alternative approaches to derive disability weights in injuries: do they make a difference? Qual Life Res 2009; 18: 657-65.
15. Mathers CD, Vos ET, Stevenson CE, Begg SJ,. The burden of disease and injury in Australia. Bull World Health Organ 2001; 79: 1076-84.
16. Stouthard M, Essink-Bot M-L, Bonsel G, et al,. Disability Weights for Diseases in the Netherlands. Amsterdam: Inst. Sociale Geneeskunde, 1997.
17. Holterhues C, Hollestein LM, Nijsten T, et al,. Burden of disease due to cutaneous melanoma has increased in the Netherlands since 1991. Br J Dermatol 2013; 169: 389-97.
18. Herdman M, Gudex C, Lloyd A, et al,. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011; 20: 1727-36.
19. Balch CM, Gershenwald JE, Soong SJ, et al,. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
20. Bergenmar M, Mansson-Brahme E, Hansson J, Brandberg Y,. Surgical resection margins do not influence health related quality of life or emotional distress in patients with cutaneous melanoma: results of a prospective randomised trial. Scand J Plast Reconstr Surg Hand Surg 2010; 44: 146-55.
21. Tsuchiya A, Dolan P,. The QALY model and individual preferences for health states and health profiles over time: a systematic review of the literature. Med Decis Making 2005; 25: 460-7.
22. Schlesinger-Raab A, Schubert-Fritschle G, Hein R, et al,. Quality of life in localised malignant melanoma. Ann Oncol 2010; 21: 2428-35.
23. Eggermont AM, Suciu S, Testori A, et al,. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012; 48: 218-25.
24. Janssen MF, Pickard AS, Golicki D, et al,. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res 2013; 22: 1717-27.
25. FACIT. Functional Assessment of Chronic Illness Therapy. Available at: http://www.facit.org/FACITOrg/Questionnaires (last accessed on 11 November 2014).
26. EuroQol. EQ-5D-5L user guide. Available at: http://www.euroqol.org/fileadmin/user-upload/Documenten/PDF/Folders-Flyers/UserGuide-EQ-5D-5L-v2.0-October-2013.pdf (last accessed on 11 November 2014).
27. Cleemput I,. A social preference valuations set for EQ-5D health states in Flanders, Belgium. Eur J Health Econ 2010; 11: 205-13.
28. Haagsma JA, van Beeck EF, Polinder S, et al,. The effect of comorbidity on health-related quality of life for injury patients in the first year following injury: comparison of three comorbidity adjustment approaches. Popul Health Metr 2011; 9: 10.
29. Hoeymans N, van Lindert H, Westert GP,. The health status of the Dutch population as assessed by the EQ-6D. Qual Life Res 2005; 14: 655-63.
30. R Foundation for Statistical Computing. R: A language and environment for statistical computing. Available at: http://www.r-project.org/ (last accessed on 11 November 2013).
31. Robert C, Thomas L, Bondarenko I, et al,. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26.
32. Sosman JA, Kim KB, Schuchter L, et al,. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-14.
33. Luyten J, Marais C, Hens N, et al,. Imputing QALYs from single time point health state descriptions on the EQ-5D and the SF-6D: a comparison of methods for hepatitis a patients. Value Health 2011; 14: 282-90.
34. Holterhues C, Cornish D, van de Poll-Franse LV, et al,. Impact of melanoma on patients' lives among 562 survivors: a Dutch population-based study. Arch Dermatol 2011; 147: 177-85.
35. König HH, Bernert S, Angermeyer MC, et al,. Comparison of population health status in six european countries: results of a representative survey using the EQ-5D questionnaire. Med Care 2009; 47: 255-61.
36. Bernert S, Fernandez A, Haro JM, et al,. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries. Value Health 2009; 12: 750-8.
37. Schubert-Fritschle G, Schlesinger-Raab A, Hein R, et al,. Quality of life and comorbidity in localized malignant melanoma: results of a German population-based cohort study. Int J Dermatol 2013; 52: 693-704.
38. de Vries M, Hoekstra HJ, Hoekstra-Weebers JE,. Quality of life after axillary or groin sentinel lymph node biopsy, with or without completion lymph node dissection, in patients with cutaneous melanoma. Ann Surg Oncol 2009; 16: 2840-7.
39. Sprangers MA, Schwartz CE,. The challenge of response shift for quality-of-life-based clinical oncology research. Ann Oncol 1999; 10: 747-9.
40. Szende A, Williams A,. Measuring Self-Reported Population Health: An International Perspective based on EQ-5D. Available at: http://www.euroqol.org/fileadmin/user005Fupload/Documenten/PDF/Books/Measuring-Self-Reported-Population-Health-An-International-Perspective-based-on-EQ-5D.pdf (last accessed on 11 November 2014).
41. Askew RL, Swartz RJ, Xing Y, et al,. Mapping FACT-melanoma quality-of-life scores to EQ-5D health utility weights. Value Health 2011; 14: 900-6.
42. Fong ZV, Tanabe KK,. Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. Br J Dermatol 2014; 170: 20-30.
43. Burdon-Jones D, Thomas P, Baker R,. Quality of life issues in nonmetastatic skin cancer. Br J Dermatol 2010; 162: 147-51.